Vitamin D and Semaglutide: What a 2026 Cohort Study Found

Before starting semaglutide, most people focus on the injection schedule, possible side effects, and expected results. A 2026 cohort study looked at a different variable: whether a person's vitamin D level before starting treatment is associated with how they respond to it.

What the study found

Researchers followed 5,384 adults with type 2 diabetes who started semaglutide, all of whom had a baseline 25-hydroxyvitamin D, or 25(OH)D, level on record. Compared with patients whose baseline vitamin D was below 15 ng/mL, those with a baseline level of 15 to 25 ng/mL had a modestly larger drop in HbA1c (an average of about 0.08 percentage points more) and a modestly larger drop in body mass index (an average of about 1.0 point more). Patients with a baseline level above 25 ng/mL had a similarly modest advantage: about 0.10 percentage points more HbA1c reduction and about 1.3 points more BMI reduction. All of these differences were statistically significant, and all of them are small in absolute terms. This is a retrospective, observational study. It shows an association between baseline vitamin D and outcomes in this population; it does not prove that raising vitamin D before starting semaglutide will produce a specific amount of extra weight loss or blood sugar improvement, and the population studied was adults with type 2 diabetes rather than the general population using semaglutide for weight management.

Why the mechanism is plausible

Vitamin D functions as a hormone that affects insulin sensitivity and pancreatic beta-cell function, in addition to its role in bone health. Low vitamin D status has been linked in other research to worse insulin sensitivity and more inflammation, both of which are relevant to how well a GLP-1 medication works. That background makes the study's finding biologically plausible, even though the size of the effect in this particular study was modest, not dramatic.

What to ask your provider

Checking a 25(OH)D level before starting semaglutide, or at any point during treatment, is a reasonable and low-cost step, particularly if you live in a northern climate, spend most of your time indoors, or have a history of poor metabolic health. If your level comes back low, your provider may recommend a vitamin D supplement, often paired with vitamin K2 and magnesium, with a retest some weeks later to confirm the level has moved into a normal range. The specific amount and duration of any supplement is a decision for you and your provider, based on how deficient you are and how your body responds; it is not something a general article can safely prescribe for you.

Where Truthe fits

Truthe's Daily Support multivitamin includes vitamin D as part of its formulation and is one option for supporting an adequate baseline, alongside whatever your provider recommends based on your own lab results. If you and a licensed provider decide that a GLP-1 medication belongs in your plan, the Truthe Rx LEAN program offers semaglutide or tirzepatide to adults. Truthe does not prescribe, and an independent licensed provider decides whether a prescription is appropriate for you.

Disclaimer: This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider.

Sources

1. Israel A, et al. Baseline vitamin D status is associated with glycemic and weight loss outcomes in patients with type 2 diabetes treated with semaglutide. Front Nutr. 2026. pubmed.ncbi.nlm.nih.gov/42125318